Latest Breaking News On - இணை சிகிச்சை இன்க் - Page 3 : comparemela.com
iCo Therapeutics Inc : iCo Therapeutics, Inc Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc Announces Warrant Exercises
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc.: iCo Therapeutics Inc: Unaware of Any Material Change
. (TSXV: ICO) (OTCQB: ICOTF) (
iCo or the
Company ). At the request of IIROC, iCo Therapeutics Inc. (the Company ) wishes to confirm that the Company s management is unaware of any material change in the Company s operations that would account for the recent increase in market activity.
About iCo Therapeutics
iCo is Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Adial Pharmaceuticals Appoints Dr Jack Reich as Head of Regulatory
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Adial Pharmaceutical, Inc.: Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich as Head of Regulatory, effective December 14, 2020. As part of his transition to Company management, Dr. Reich stepped down from the Board of Directors to serve in his new full-time role.
Dr. Jack Reich s career spans over 35 years in the pharmaceutical, biotechnology, and venture capital industries. Since 1987, Dr. Reich has been involved in more than 30 medical and biotech companies. He was a founding officer of Gensia, Inc. and co-founded the first gene therapy company, Viagene, Inc. Following its public listing, Gensia soon became the second-largest market cap biotech on NASDAQ, and Viagene was acquired by Chiron after its public listing. Dr. Reich also co-founded the first cardiovascul